Breast Cancer Trial, Recruiting (NCT04480203)

Breast Cancer Trial, Recruiting NCT04480203 Sponsor: Norwegian Institute of Public Health Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04480203 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with breast cancer for the first time on or after January 1, 2020
People whose breast cancer has not spread to other parts of the body (classified as stage 0 through to stage III)
People whose tumour tests positive for a protein called HER2 (regardless of other hormone receptor results), OR whose tumour tests negative for oestrogen receptors (ER negative)
People with oestrogen receptor-positive (ER+) tumours may also be considered in the future, as long as including them does not conflict with recruitment for two other studies called EMIT and OPTIMA (confirm with trial site)

Who may not be able to join:

There are no listed exclusion criteria for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Giske Ursin, MD, PhD, Norwegian Institute of Public Health

Phone: +4722451300

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04480203

Sponsor: Norwegian Institute of Public Health

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: +4722451300

More information: https://clinicaltrials.gov/study/NCT04480203

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with breast cancer for the first time on or after January 1, 2020
People whose breast cancer has not spread to other parts of the body (classified as stage 0 through to stage III)
People whose tumour tests positive for a protein called HER2 (regardless of other hormone receptor results), OR whose tumour tests negative for oestrogen receptors (ER negative)
People with oestrogen receptor-positive (ER+) tumours may also be considered in the future, as long as including them does not conflict with recruitment for two other studies called EMIT and OPTIMA (confirm with trial site)

Who may not be able to join:

There are no listed exclusion criteria for this trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Norwegian Institute of Public Health

Registry

ClinicalTrials.gov

Start date

15 January 2021

Est. completion

31 August 2023

Where this trial is recruiting

🇳🇴 Norway

Primary endpoints

Stress

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov